Journal of Correctional Health Care, published by Mary Ann Liebert, Inc, is a vital publication that addresses the crucial intersection of health care, justice systems, and public health. With ISSN 1078-3458 and E-ISSN 1940-5200, this journal has been a leading source of research and analysis in correctional health since its inception in 1994. As of 2023, it holds an esteemed ranking within the Q2 quartile for Community and Home Care and Q3 for Public Health, Environmental and Occupational Health, reflecting its significant contribution to these fields. The Journal of Correctional Health Care focuses on the healthcare needs of incarcerated populations, providing a platform for innovative research, comprehensive reviews, and policy analysis. Researchers, professionals, and students alike will find invaluable insights that bridge gaps in knowledge and practice, emphasizing the importance of equitable health care within correctional settings. This journal continues to shape discussions and influence practices aimed at enhancing health outcomes in these vulnerable communities.

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

JCO Global Oncology is a premier open-access journal published by Lippincott Williams & Wilkins, dedicated to the dissemination of high-quality research in the fields of cancer research and oncology. Since its inception in 2020, this journal has rapidly established itself as a vital resource for researchers, healthcare professionals, and students, holding a distinguished position in the Q2 category for both Cancer Research and Oncology based on the latest metrics. With an impressive Scopus rank of #61 out of 636 in General Medicine, the journal is recognized for its rigorous peer-reviewed articles and cutting-edge insights into oncological science. The open-access model ensures that vital research is readily available to a global audience, fostering collaborative advancements in the fight against cancer. JCO Global Oncology explores a broad range of topics and encourages submissions that contribute to the understanding, prevention, and treatment of various malignancies. With its substantial impact and ongoing contributions to the field, it stands as a promising platform for advancing oncological discourse and knowledge.

International Journal of Tuberculosis and Lung Disease is a leading peer-reviewed journal published by the International Union Against Tuberculosis and Lung Disease (IUATLD). Since its inception in 1997, this journal has dedicated itself to disseminating groundbreaking research and advancements in the prevention, diagnosis, and treatment of tuberculosis and related respiratory conditions. With an impressive impact factor and respected quartile rankings—Q1 in Miscellaneous Medicine and Q2 in both Infectious Diseases and Pulmonary and Respiratory Medicine—this journal serves as a vital resource for researchers, healthcare professionals, and students alike. Its publication spans diverse fields, ensuring comprehensive coverage of the latest findings and trends in respiratory health. Although it does not offer Open Access, the journal's commitment to high academic standards and innovative research makes it essential reading for anyone involved in the fight against lung disease. The journal is based in Paris, France, and continues to provide invaluable insights that drive global health initiatives and clinical practices in tuberculosis management.

JAIDS - Journal of Acquired Immune Deficiency Syndromes, is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamics of HIV/AIDS and its broader implications in the fields of infectious diseases and pharmacology. With an esteemed impact factor that places it in the prestigious Q1 category for both Infectious Diseases and Pharmacology (medical) as of 2023, this journal aims to provide a platform for groundbreaking research, clinical findings, and innovative therapies relevant to the management and prevention of HIV/AIDS. The journal's rigorous editorial standards and commitment to advancing knowledge make it an essential resource for researchers, healthcare professionals, and students invested in the global response to AIDS. Although the journal does not currently offer open access options, it remains instrumental in disseminating high-quality research that shapes clinical practices and policy developments in the field.

AIDS RESEARCH AND HUMAN RETROVIRUSES, published by Mary Ann Liebert, Inc., is a pivotal journal dedicated to advancing the field of HIV research and the broader spectrum of human retroviruses. With an ISSN of 0889-2229 and an E-ISSN of 1931-8405, this journal has been in continuous publication since 1987 and is respected in the academic community for its rigorous peer-reviewed articles. As a Q3 ranked journal in Immunology, Infectious Diseases, and Virology as of 2023, it plays a crucial role in disseminating cutting-edge research, theoretical advancements, and clinical insights that contribute significantly to the understanding and treatment of HIV and related disorders. The journal's objective is to foster collaboration among researchers, healthcare professionals, and educators by providing a platform for the exchange of innovative ideas and findings. Although not an open-access journal, its compelling content ensures that it remains a primary resource for those in the academic and medical communities tackling the challenges posed by retroviral infections. With a commitment to excellence and relevance, AIDS RESEARCH AND HUMAN RETROVIRUSES continues to shape the future of research in this critical area.

HIV Medicine is a prestigious journal published by Wiley that stands at the forefront of research in the fields of health policy, infectious diseases, and pharmacology, with a commendable impact factor reflected in its Q1 rankings for 2023. Established in 1999 and set to converge its expertise through 2024, this journal plays a critical role in advancing the understanding and treatment of HIV and related health challenges. It is esteemed for its rigorous peer-review process and its contributions to both clinical and policy-oriented discussions surrounding HIV medicine. With a broad international readership, it serves as a vital resource for researchers, healthcare professionals, and students committed to fighting the global HIV epidemic. Although not open access, its vital insights are indispensable for anyone involved in infectious disease research and healthcare policy. Articles published in HIV Medicine shape global health strategies and influence the future of HIV research, making it a must-read for those dedicated to this crucial field.

AJAR - African Journal of AIDS Research, an esteemed publication by Taylor & Francis Ltd, stands at the forefront of research in the field of HIV/AIDS, with a specific focus on the African continent. Established in 2003 and publishing continuously through 2024, this journal serves as a crucial platform for disseminating innovative research findings aimed at addressing the challenges of HIV/AIDS. With its ISSN 1608-5906 and E-ISSN 1727-9445, AJAR is indexed in prominent databases and holds a respectable Q3 rating in major categories such as Infectious Diseases, Medicine, Public Health, and Virology as of 2023. This positions the journal as a relevant resource for scholars and medical professionals looking to stay informed on the latest developments and strategies in AIDS research. Although it is not currently an open-access journal, AJAR provides readers with valuable insights that are essential for advancing public health initiatives and infectious disease research across Africa and beyond. The journal's commitment to high-quality peer-reviewed research underscores its importance within its field, making it a vital resource for researchers, students, and policymakers alike.

AIDS Research and Therapy is a prestigious peer-reviewed journal dedicated to disseminating cutting-edge research in the fields of AIDS and HIV therapy. Published by BMC, this Open Access journal has been freely available since its inception in 2004, facilitating global access to vital research findings. Based in the United Kingdom, the journal covers a diverse range of topics including molecular medicine, pharmacology, and virology, making it a crucial resource for researchers and clinicians alike. Recognized for its strong impact within the scientific community, it holds a Q2 quartile ranking in multiple categories as of 2023, including Molecular Medicine and Pharmacology. With an aim to enhance understanding and improve clinical outcomes for those affected by HIV/AIDS, AIDS Research and Therapy serves as an essential platform for the exchange of innovative ideas and practices that can inform future therapies and interventions. Researchers, professionals, and students seeking high-quality, peer-reviewed content will find this journal invaluable in advancing their knowledge and efforts in combating the HIV/AIDS epidemic.

Transgender Health is an esteemed academic journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of transgender health and well-being. With an ISSN of 2688-4887 and an E-ISSN of 2380-193X, the journal aims to disseminate high-quality, peer-reviewed research that addresses the health disparities and unique medical needs of transgender individuals. Recognized for its scholarly impact, Transgender Health boasts a Q1 ranking in Gender Studies and a Q2 ranking in Medicine (miscellaneous) as of 2023, reflecting its significance in both social and clinical arenas. The journal's rigorous approach is evident in its Scopus rankings, placing it in the top 15% for Gender Studies and the top 32% for miscellaneous medical disciplines. Published continuously from 2016 to 2024, it is an essential resource for researchers, healthcare professionals, and students aiming to contribute to the discourse on transgender health. For those interested in critical developments, this journal remains a primary source of cutting-edge research and innovative practices without the constraints of open access, making it a valuable addition to the academic landscape.